We recently celebrated Rare Disease Day, and all of March is Myeloma Awareness Month. I think it's a good opportunity to talk about what the priorities are when it comes to the needs in treating this disease.
Indeed, in plasmocytic myeloma, a great deal has changed in favor of reimbursement decisions of recent years. The decision at the beginning of this year, that is, to include daratumumab-lenalidomide-dexamethasone in the reimbursement program for a group of patients ineligible for transplantation, showed that in Poland we can treat very modern, according to international standards. I am talking here about first-line treatment. First-line treatment is currently a daratumumab-bortezomib-talidomide-dexamethasone regimen for patients eligible for transplantation. Later, we have the option of both consolidation therapy with the same regimen and, finally, the administration of maintenance treatment with lenalidomide, whic...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
